15 withdrawn, 6 completed, 6 unknown, 4 terminated. 19 Phase 2, 5 Phase 1, 3 Not applicable, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Withdrawn 14, Terminated 3, Unknown 2 |
| Phase 1 | 5 | Unknown 4, Terminated 1 |
| Not applicable | 3 | Completed 2, Not yet recruiting 1 |
| Phase 3 | 2 | Completed 1, Suspended 1 |
Follow Biological Therapy: new trials by email Literature Review of Biological Therapy trials Research Report on Biological Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REverse LuNg Airway and Vascular RemOdeling in Asthma ReMission (ReNORM) Biologic Therapy - Asthma; Eosinophilic | Not applicable | Not yet recruiting | Western University, Canada | 200 | 2026-10-01 | 2026-07-31 |
| LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice Conventional Systemic Therapies, Biologic Therapies - Psoriasis, Atopic Dermatitis | Not yet recruiting | Fondazione ISIDE | 20000 | 2026-01-01 | 2026-01-15 | |
| Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma Immunotherapy, Radiotherapy - Non Small Cell Lung Cancer Metastatic | Completed | Hopitaux Prives de Metz, Groupe UNEOS | 350 | 2024-10-14 | 2025-08-08 | |
| Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease enteral nutrition, Immunotherapy, biological agents - Crohn Disease | Active not recruiting | Tongji Hospital | 100 | 2023-12-01 | 2025-09-04 | |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 | |
| Treatment Outcome of Uveitis in Autoimmune Diseases Corticosteroid Series - Autoimmune Uveitis | Unknown | Assiut University | 1 | 2019-03-01 | 2019-03-22 | |
| Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection Fidaxomicin 200 mg, fecal microbiota transplantation (FMT) - Clostridium Difficile | Phase 2 | Terminated | University of Alberta | 4 | 2019-01-21 | 2022-12-13 |
| Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL) Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy) - Stage IV Non-Small Cell Lung Cancer | Not applicable | Completed | Stanford University | 45 | 2017-06-28 | 2025-11-05 |
| Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay antitumor drug screening assay, chemotherapy, biological therapy - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Completed | University of Washington | 16 | 2013-08-02 | 2018-07-11 |
| Evaluation of Vitamin D Levels in Psoriasis Patients Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy - Psoriasis | Withdrawn | University of California, Irvine | 2013-06-01 | 2024-05-08 | ||
| Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors Biologic therapy for psoriasis - Psoriasis, Psoriatic Arthritis (PsA) | Completed | Juan Ruano Ruiz | 1000 | 2012-01-01 | 2025-06-27 | |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Non-Hodgkin's Lymphoma | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-08-01 | 2007-08-14 |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy - Leukemia, Hairy Cell Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 40 | 2007-04-01 | 2007-04-18 |
| Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease Immunotoxin therapy, CAT-8015 immunotoxin, Biological therapy - Leukemia | Phase 1 | Unknown | Cambridge Antibody Technology | 50 | 2007-03-01 | 2007-04-17 |
| Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma cisplatin, cytarabine, etoposide - AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2006-02-01 | 2016-02-03 | |
| IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma IVIG, Biological Therapy - Cancer of Colon, Malignant Melanoma | Phase 2 | Unknown | GammaCan | 30 | 2005-07-01 | 2006-10-12 |
| Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer autologous tumor cell vaccine, therapeutic autologous dendritic cells, adjuvant therapy - Lung Cancer | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 15 | 2005-02-01 | 2008-01-28 |
| Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer antibody therapy, biological therapy, muromonab-CD3 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Unknown | St. Vincent Medical Center - Los Angeles | 1991-06-01 | 2013-11-06 | |
| Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery BCG vaccine, biological therapy, fluorouracil - Colorectal Cancer | Phase 3 | Completed | NSABP Foundation Inc | 1977-09-01 | 2013-06-24 | |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer antineoplaston A10, antineoplaston AS2-1, bicalutamide - Adenocarcinoma of the Prostate, Stage III Prostate Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 |
Showing 20 of 35. Sign in to see all of them.
Colonic Neoplasms (4) · Leukemia (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Congenital Abnormalities (3) · Psoriasis (3) · Carcinoma, Islet Cell (2) · Colorectal Neoplasms (2) · Leukemia, Erythroblastic, Acute (2) · Leukemia, Megakaryoblastic, Acute (2) · Leukemia, Monocytic, Acute (2) · Leukemia, Myelomonocytic, Acute (2) · Lung Neoplasms (2)
Burzynski Research Institute (7) · Cambridge Antibody Technology (3) · Eastern Cooperative Oncology Group (2) · National Cancer Institute (NCI) (2) · AIDS Malignancy Consortium (1) · Assiut University (1) · Favrille (1) · Fondazione ISIDE (1) · GammaCan (1) · Hopitaux Prives de Metz, Groupe UNEOS (1) · Jonsson Comprehensive Cancer Center (1) · Juan Ruano Ruiz (1) · NSABP Foundation Inc (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · SWOG Cancer Research Network (1)
United States (21) · Poland (3) · Canada (2) · China (1) · France (1) · Israel (1) · Italy (1) · Spain (1) · United Kingdom (1)
Stanislaw R. Burzynski, MD, PhD (7) · Alexandra M. Levine, MD (1) · Anil Tulpule, MD (1) · Ariane Guignard, Resident (1) · Bipin N. Savani, MD (1) · Charles L. Wiseman, MD, FACP (1) · Dan Aderka, M.D. (1) · David R. Bickers, MD (1) · Dina Kao, MD (1) · Grace Parraga, PhD (1) · Hasan L Fahmy, Prof. (1) · Jacob M. Rowe, MD (1) · Jennifer Johnson, MD, PhD (1) · Jennifer Soung, M.D. (1) · John Densmore, MD (1)
PMID 15292384, PMID 18596230, PMID 23841941, PMID 29149611, PMID 3276901, PMID 41051639
P30CA015704 (1), U10CA037429 (1)